XBI

What Deleveraging May Mean For Netflix…and You

Margin debt levels have lessened, and while that might sound like sound financial planning, the reasons suggest potential markets problems More 

Bet on a Bounce with These Biotech ETFs

Biotech stocks may have taken a beating lately, but that may just make these biotech ETFs more of a bargain. More 

Be Careful Before Loving Leveraged Biotech ETFs

The new crop of triple-leveraged biotech ETFs have had staggering returns (and losses), serving as a reminder that not all investors should be involved with leveraged ETFs. More 

3 Charts That Tell Us About the Stock Market in October

The economy continues to struggle, employment is still weak, and markets are vulnerable. Here's how we're going to position our portfolio More 

Biotech Stocks: Is It Safe to Come out Now? (IBB, XBI)

Biotech stocks are getting smashed this week, but betting against the sector remains a bad idea. The only trick is getting the timing right. More 

The Best Way to Buy Biotech Stocks: A Heated Debate

Among ETFs that hold biotech stocks, XBI looks like a winner, holding the advantages of equal-weighting and exposure to some potential highfliers. More 

7 Dirt-Cheap Ways to Supercharge Your Portfolio

Looking to juice your dividends? Get aggressive with growth? Well, these are some of the best ETFs to get the job done on the cheap. More